chufangao/CTO huggingface dataset:
Clinical trial NCT05088967: Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
Official title: A Randomized, Open-label, Phase Ib Clinical Study to Evaluate the Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Development strategy adjustment
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-02
Primary completion date: 2021-12-31
Completion date: 2023-12-25
Plan to share individual participant data: NO
Clinical trial NCT03443973: Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
Official title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
Enrollment: 975.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-22
Primary completion date: 2022-09-23
Completion date: 2022-11-28
Baseline population: Intent-to-treat (ITT) analysis set included all participants randomized during the global phase, who received at least one dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT04826484: Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel
Official title: A Randomized Trial Evaluating Use of Long-Acting Liposomal Bupivacaine (Exparel®) in Reducing Narcotic Pain Requirements in Pediatric Patients Undergoing Minor Urologic Procedures
Acronym: Baby ORIOLES
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Met futility threshold at interim analysis
Enrollment: 104.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-01
Primary completion date: 2023-04-26
Completion date: 2023-04-26
Limitations and caveats: The trial met the predetermined threshold for early stopping.~1. Inability to blind surgeons due to differences in the appearance of the agents.~2. Unclear if the absorption profile of intervention is more rapid in groin/dorsal penile tissue compared to other areas.~3. Our cohort was enriched with low morbidity procedures which may have decreased differences between arms~4. Inability to compare the efficacy of the agents stratified by procedure type due to low enrollment in each procedure
Plan to share individual participant data: NO
Clinical trial NCT05518422: Role of Endothelin-1 Modulating Insulin-stimulated Blood Flow and Sympathetic Nervous System Activity in Obesity
Official title: Role of Endothelin-1 Modulating Insulin-stimulated Blood Flow and Sympathetic Nervous System Activity in Obesity
Sponsor: University of Missouri-Columbia (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-02-29
Primary completion date: 2024-02-29
Completion date: 2024-02-29
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05221320: Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
Official title: A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced GI Malignancies Harboring Mitogen-activated Protein Kinase (MAPK) Pathway Mutations (BVD-523-HCQ)
Sponsor: BioMed Valley Discoveries, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of Enrollment for Remaining Open Baskets
Enrollment: 47.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-26
Primary completion date: 2024-05-08
Completion date: 2024-07-14
Plan to share individual participant data: NO
Clinical trial NCT03128619: Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Official title: A Phase Ib Trial Evaluating the Safety of Copanlisib, Letrozole, and Palbociclib in Metastatic Breast Cancer and Phase II Trial Comparing the Molecular Effects of Neoadjuvant Copanlisib in Combination With Palbociclib and Letrozole, vs. Copanlisib With Letrozole, vs. Palbociclib With Letrozole for Patients With Hormone Receptor Positive, HER2 Normal Breast Cancer
Sponsor: Jonsson Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Insufficient accrual
Enrollment: 10.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-08-02
Primary completion date: 2022-03-31
Completion date: 2022-03-31
Clinical trial NCT04116203: Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS)
Official title: Dietary Fish Oil Intervention in Polycystic Ovary Syndrome
Acronym: PCOS
Sponsor: University of Alberta (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: waiting for additional funding to complete trial
Enrollment: 180.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2016-06-30
Primary completion date: 2024-12-30
Completion date: 2024-12-30
Plan to share individual participant data: NO
IPD sharing description: There will be no sharing with other researchers.
Clinical trial NCT03560011: Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome
Official title: Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome
Acronym: RITUXIVIG
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: SUSPENDED 
Why stopped: Decision of Data Safety Monitoring Board
Enrollment: 90.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2019-04-03
Primary completion date: 2021-01-07
Completion date: 2022-11-04
Plan to share individual participant data: YES
Clinical trial NCT03003728: 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
Official title: 2015-10: A Phase II Pilot Study of Expanded Natural Killer Cells and Elotuzumab to Eradicate High-Risk Myeloma Post Autologous Stem Cell Transplant
Sponsor: University of Arkansas (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Withdrawal of study support
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-01
Primary completion date: 2020-07-08
Completion date: 2020-07-08
Clinical trial NCT05027815: Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
Official title: A Phase 1/2a Study of Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells (cePolyTregs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With SARS-CoV-2 Infection (regARDS)
Acronym: regARDS
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Decrease in COVID-19 cases made further enrollment infeasible.
Enrollment: 7.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-09-23
Primary completion date: 2022-03-02
Completion date: 2022-03-02
Limitations and caveats: The trial was terminated early due to a decline in the available participants, which prevent the analysis of some secondary and exploratory endpoints from completion as initially planned. The safety and tolerability, and recommended phase 2 dose can not be determined based on the limited data.
Plan to share individual participant data: NO
Clinical trial NCT03868839: Telmisartan Pilot Study on Treatment Resistant Schizophrenia
Official title: An Open-label Feasibility Trial of Adjunctive Telmisartan in Patients With Treatment Resistant Schizophrenia
Sponsor: University of Massachusetts, Worcester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of funding
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-01
Primary completion date: 2020-10-07
Completion date: 2020-10-07
Baseline population: Study is terminated due to lack of funding.
Limitations and caveats: The overall limitations and caveat is that this study is a pilot study with small sample size (6 subjects).
Plan to share individual participant data: NO
Clinical trial NCT03126461: SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
Official title: Phase 2 Trial of SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: the project was never initiated and no participants were enrolled, it was closed permanently
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-01
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT03280056: Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
Official title: A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS
Sponsor: Brainstorm-Cell Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 196.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-28
Primary completion date: 2020-09-29
Completion date: 2020-09-29
Baseline population: Demographic characteristics were balanced between NurOwn and placebo treatment groups with no statistically significant differences at baseline.
Limitations and caveats: This trial had a unique and atypical trial population that included more participants than anticipated with advanced ALS, who had a low ALSFRS-R score. As compared with recent large ALS clinical trials, this study population is an outlier, with a mean overall ALSFRS-R score at baseline lower than other studies, and this impacted the power of this study.
Plan to share individual participant data: NO
Clinical trial NCT03674827: Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Official title: A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFICATION OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN-2 (VBIR-2) (PF-06936308) FOR ADVANCED NON-SMALL CELL LUNG CANCER AND METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology portfolio; the study was not terminated because of safety concerns.
Enrollment: 36.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-27
Primary completion date: 2021-09-27
Completion date: 2021-09-27
Baseline population: All enrolled participants who received at least 1 dose of one of the components of the regimen.
Limitations and caveats: This study was terminated on 10 Feb 2021 by the Sponsor. The decision to terminate this study was based on the results of a strategic evaluation of VBIR-2 within the current Sponsor's oncology portfolio. When the decision of study termination was made, participants enrolled in Part 1 who were still on study were to remain on treatment until 31 Aug 2021; Part 2 of the study was never opened.
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03341962: Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of IMU-838 for Induction and Maintenance Therapy in Moderate-to-severe Ulcerative Colitis
Acronym: CALDOSE-1
Sponsor: Immunic AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Considering the efficacy results of the induction phase (allowed use of corticosteroids as concomitant medication) in the study population and since IMU-838 did not show superiority over placebo, the OLE was prematurely closed by the sponsor.
Enrollment: 263.0 (ACTUAL)
Number of arms: 8.0
Start date: 2018-03-15
Primary completion date: 2022-11-16
Completion date: 2022-11-16
Baseline population: In the IP, one patient received erroneously 30 mg IMU-838 instead of placebo and was included in the 30 mg IMU-838 group for the safety analysis set (SAF), as in participant flow, but in the placebo group for the full analysis set (FAS). Demographics and baseline characteristics were analyzed for the FAS.~Not all participants who completed or discontinued the IP continued to the MP or OLE. Patients were re-randomized at the start of MP (except the placebo group).
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05312970: Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)
Official title: A Phase 4 Randomized Trial Comparing Varithena to Endothermal Ablation for the Treatment of the Great Saphenous Vein
Acronym: VERITAS
Sponsor: Boston Scientific Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Enrollment challenges and a difficult insurance coverage landscape
Enrollment: 43.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-02-10
Primary completion date: 2024-04-04
Completion date: 2024-04-04
Plan to share individual participant data: NO
Clinical trial NCT03385057: Postoperative Ibuprofen Use and Risk of Bleeding in Pediatric Tonsillectomy
Official title: Postoperative Ibuprofen Use and Risk of Bleeding in Pediatric Tonsillectomy
Sponsor: Massachusetts Eye and Ear Infirmary (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study design flaws; research design needed to be reconfigured
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-30
Primary completion date: 2023-01-01
Completion date: 2023-01-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04578548: A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Official title: An Exploratory, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Orally Administered GLPG2737 for 52 Weeks, Followed by an Open-label Extension Period of 52 Weeks in Participants With Autosomal Dominant Polycystic Kidney Disease
Sponsor: Galapagos NV (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was early terminated due to lack of efficacy.
Enrollment: 66.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-10
Primary completion date: 2022-12-14
Completion date: 2023-04-04
Baseline population: Safety Analysis Set (SAS): All randomized participants who received at least one dose of study drug.
Limitations and caveats: The early termination was decided due to the lack of efficacy of GLPG2737, making the expected benefit-risk balance negative.
Plan to share individual participant data: NO
Clinical trial NCT05372887: Safety and Efficacy Study of TNX-102 SL in Participants With PTSD
Official title: A Phase 2, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Daily Bedtime TNX-102 SL in Participants With PTSD
Sponsor: Tonix Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The study was stopped due to business reasons.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-14
Primary completion date: 2022-11-08
Completion date: 2022-11-08
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03705637: Liposomal Bupivicaine for Skin Graft Donor Sites in Burn Patients
Official title: Evaluation of Liposomal Bipivicaine in Split Thickness Skin Graft Donor Sites in Burn Patients
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Patient population too low to reasonably continue study, pandemic had started at time of cessation, further leading to study discontinuation.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-01
Primary completion date: 2020-03-24
Completion date: 2020-03-24
Plan to share individual participant data: NO
IPD sharing description: IPD will not be shared with other researchers outside of those directly involved in this study.
Clinical trial NCT03457818: Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab
Official title: Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to enrollment difficulties compounded by the COVID pandemic.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-07
Primary completion date: 2020-06-10
Completion date: 2020-06-10
Baseline population: Study terminated
Limitations and caveats: The study was terminated due to poor enrollment compounded by the COVID-19 pandemic. Data was not collected.
Plan to share individual participant data: NO
Clinical trial NCT03486327: Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
Official title: Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
Sponsor: Bracco Diagnostics, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision; expiration of available study agent due to long recruitment timeline.
Enrollment: 4.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-19
Primary completion date: 2020-11-13
Completion date: 2021-07-31
Baseline population: As of July 31, 2021, enrollment was terminated for Study BR55-110 due to expiration of available BR55. Therefore, only 4 participants were enrolled in the first cohort of this study (0.03 mL/kg). No participant was enrolled in the 0.05 mL/kg or 0.08 mL/kg groups.
Plan to share individual participant data: NO
Clinical trial NCT02088112: MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
Official title: A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Gefitinib in Combination With MEDI4736 (Anti PD-L1) in Subjects With Non-Small Cell Lung Cancer(NSCLC)
Sponsor: MedImmune LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 56.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-03-24
Primary completion date: 2021-03-09
Completion date: 2021-03-09
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04265261: A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
Official title: A Randomized, Double-Masked, 48-Week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
Acronym: CANBERRA
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 139.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-06-05
Primary completion date: 2023-07-19
Completion date: 2023-07-19
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT03754140: Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
Official title: Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
Acronym: INTRANS
Sponsor: Melanoma Institute Australia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Unable to identify eligible patients within planned timeframe
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-20
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT03988231: Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study
Official title: Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Funding was not received.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-31
Primary completion date: 2022-06-30
Completion date: 2023-06-30
Plan to share individual participant data: UNDECIDED